

10

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 55130

Manuscript Type: CASE REPORT

5

Effect of Chidamide on treating hepatosplenic T-cell lymphoma: A case report

Wang XT *et al.* Chidamide: A promising treatment option for HSTCL

Xing-Tong Wang, Wei Guo, Mo Sun, Wei Han, Zhong-Hua Du, Xiu-Xiu Wang,

Bei-Bei Du, Ou Bai

Abstract

BACKGROUND

Match Overview



3 matches

1	Internet 65 words crawled on 10-Apr-2020 pericles.pericles-prod.literatumonline.com	3%
2	Internet 63 words crawled on 01-May-2020 www.dovepress.com	3%
3	Internet 57 words crawled on 27-Feb-2020 www.wjgnet.com	3%
4	Internet 26 words crawled on 05-Jun-2020 www.frontiersin.org	1%
5	Crossref 20 words Ying Wu, Lei Wang, Yahui Huang, Shuqiang Chen, Shan chao Wu, Guoqiang Dong, Chunquan Sheng. "Nicotina	1%
6	Crossref 18 words Julio Finalet Ferreira, Leila Rouhigharabaei, Helena Urb ankova, Jo-Anne van der Krogt et al. "Integrative Genomi	1%
7	Crossref 17 words Mariko Yabe, Roberto N. Miranda, L. Jeffrey Medeiros. "H epatosplenic T-cell Lymphoma: a review of clinicopathi ...	1%
8	Internet 17 words crawled on 22-May-2018 archivesofpathology.org	1%
9	Internet 14 words crawled on 25-Apr-2016 www.science.gov	1%
10	Internet 14 words crawled on 15-Jun-2020 f6publishing.blob.core.windows.net	1%
11	Crossref 11 words Yabe, Mariko, L. Jeffrey Medeiros, Yahya Daneshbod, Ma soud Davanlou, Carlos E. Bueso-Ramos, Elisa J. Mora	<1%



ALL

IMAGES

VIDEOS

11,400 Results

Any time ▾

Therapeutic effect of chidamide on relapsed refractory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943875>

Jan 12, 2018 · **Chidamide**, a selective oral inhibitor for histone deacetylase, is the first new drug approved for the treatment of relapsed or refractory peripheral T cell **lymphoma** in China. Herein, we report a case of refractory AITL admitted at our hospital, which has achieved obvious curative effect after treatment with **chidamide**.

Author: Jingxia Jin, Cuiping Zheng, Shenghao ... Publish Year: 2018

Chidamide Combined With PECM in Relapsed or Refractory ...

<https://clinicaltrials.gov/ct2/show/NCT03321890> ▾

Oct 26, 2017 · **Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma** (PTCL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

A Single-arm, Open, Phase II Study of Chidamide Combined ...

<https://www.clinicaltrials.gov/ct2/show/NCT04025931> ▾

Jul 19, 2019 · **Chidamide** is a new chemical structure benzamide HDAC inhibitor developed independently in China. It has the selectivity of HDAC subtypes and unique efficacy. In a phase II clinical study of **Chidamide** in the treatment of peripheral T-cell **lymphoma** in China in 2009, 79 patients with recurrent or refractory **lymphoma** had ORR of 27.9%.

A patient with plasmablastic lymphoma achieving long-term ...

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4561-9> ▾

Jun 08, 2018 · No standard of care is established for plasmablastic **lymphoma** (PBL) and prognosis remains extremely poor, given that patients relapse early after **chemotherapy** and display resistance to commonly applied cytostatic drugs. We report a case of nodal, HIV-unrelated PBL in a patient who achieved and maintained a very long lasting complete remission after an intensive **therapy** ...

Author: Alessandro Broccoli, Laura Nanni, Vitt... Publish Year: 2018

Circulating PD-1 (+) cells may participate in immune ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536954>

Apr 10, 2019 · Peripheral T-cell **lymphoma** (PTCL) is a heterogeneous disease with poor outcomes. We



Effect of Chidamide on treating hepatosplenic T-cell lymphoma: A



ALL

IMAGES

VIDEOS

2,900,000 Results

Any time ▾

[Therapeutic effect of chidamide on relapsed refractory ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943875>

Chidamide, a selective oral inhibitor for histone deacetylase, is the first new drug approved for the treatment of relapsed or refractory peripheral T cell lymphoma in China. Herein, we report a case of refractory AITL admitted at our hospital, which has achieved obvious curative effect after treatment with chidamide.

Author: Jingxia Jin, Cuiping Zheng, Shenghao ... Publish Year: 2018

[Therapeutic effect of chidamide on relapsed refractory ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/29480865>

INTRODUCTION: Angioimmunoblastic T-cell lymphoma (AITL) is a kind of rare peripheral T cell lymphoma, which usually has acute onset at old age. MATERIALS AND METHODS: Here we report a case of relapsed refractory AITL, which has achieved obvious curative effect after treatment with chidamide.

Author: Jingxia Jin, Cuiping Zheng, Shenghao ... Publish Year: 2018

[Effective remission of chidamide on treatment of advanced ...](#)

<https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.12944>

Mycosis fungoides (MF) and Sézary syndrome are the most common types of primary cutaneous T cell lymphoma, which primarily involves skin without curative treatment. We report a case of a 29-year-old female Chinese patient, who developed multiple cutaneous lesions gradually for 5 years.

Author: Yuxuan Che, Xiaolei Ding, Jincheng S... Publish Year: 2019

PEOPLE ALSO ASK

What percentage of Hodgkin s lymphoma is T cell?



What are the early symptoms of cutaneous T cell lymphoma?



How does T cell lymphoma affect the body?



What is the best treatment for T cell lymphoma?





Effect of Chidamide on treating hepatosplenic T-cell lym



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

2,900,000 Results

Any time ▾

[Therapeutic effect of chidamide on relapsed refractory ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943875>

Chidamide, a selective oral inhibitor for histone deacetylase, is the first new drug approved for the **treatment** of relapsed or refractory peripheral **T cell lymphoma** in China. Herein, we **report a case** of refractory AITL admitted at our hospital, which has achieved obvious curative **effect** after **treatment** with **chidamide**.

Author: Jingxia Jin, Cuiping Zheng, Shenghao... **Publish Year:** 2018

[Therapeutic effect of chidamide on relapsed refractory ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/29480865>

INTRODUCTION: Angioimmunoblastic **T-cell lymphoma** (AITL) is a kind of rare peripheral **T cell lymphoma**, which usually has acute onset at old age. MATERIALS AND METHODS: Here we **report a case** of relapsed refractory AITL, which has achieved obvious curative **effect** after **treatment** with **chidamide**.

Author: Jingxia Jin, Cuiping Zheng, Shenghao... **Publish Year:** 2018

[Effective remission of chidamide on treatment of advanced ...](#)

<https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.12944>

Mycosis fungoides (MF) and Sézary syndrome are the most common types of primary cutaneous **T cell lymphoma**, which primarily involves skin without curative **treatment**. We **report a case** of a 29-year-old female Chinese patient, who developed multiple cutaneous lesions gradually for 5 years.

Author: Yuxuan Che, Xiaolei Ding, Jincheng S... **Publish Year:** 2019

PEOPLE ALSO ASK

What percentage of Hodgkin s lymphoma is T cell? ▾

What are the early symptoms of cutaneous T cell lymphoma? ▾